# Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents

Study · id `cardio:ct-nct04287387` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04287387](<https://clinicaltrials.gov/study/NCT04287387>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04287387

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 180 participants.

## Technical summary

Registry record NCT04287387. Randomized; no masking; primary purpose treatment. Start 2020-03-02 (anticipated); primary completion 2021-03-02 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 180 participants (planned count; ClinicalTrials.gov record NCT04287387, source copy `cardio:ctgov-nct04287387-2020-02-27`, retrieved 2026-10-26)
- Planned start: 2020-03-02 (anticipated) (ClinicalTrials.gov record NCT04287387, source copy `cardio:ctgov-nct04287387-2020-02-27`, retrieved 2026-10-26)
- Primary completion: 2021-03-02 (anticipated) (ClinicalTrials.gov record NCT04287387, source copy `cardio:ctgov-nct04287387-2020-02-27`, retrieved 2026-10-26)
- Completion: 2021-03-02 (anticipated) (ClinicalTrials.gov record NCT04287387, source copy `cardio:ctgov-nct04287387-2020-02-27`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04287387, source copy `cardio:ctgov-nct04287387-2020-02-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04287387-2020-02-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents
- Condition: Type2 Diabetes Mellitus
- Intervention (Drug): Glucophage 500Mg Tablet
- Intervention (Drug): Acarbose Tablets
- Intervention (Drug): Sitagliptin tablet
- Intervention (Drug): Dapagliflozin Tablet
- Intervention (Drug): Pioglitazone Tablets
- Intervention (Drug): Glimepiride Tablets
- Lead sponsor: Peking Union Medical College Hospital
- Lead sponsor class: OTHER
- Collaborator: Chinese Academy of Sciences
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Peking Union Medical College Hospital (`cardio:org-peking-union-medical-college-hospital`)

## Provenance

Content hash: 5abf600c6a029e9a454c211d90744db24b8bcebe2e8cb2f3cb29e9db66a77f94
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
